Get the Stockscreener App
71.53
0.46%
0.33
After Hours:
71.53
Edwards Lifesciences Corp stock is traded at $71.53, with a volume of 3.24M.
It is up +0.46% in the last 24 hours and up +1.27% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$71.20
Open:
$71.28
24h Volume:
3.24M
Relative Volume:
0.74
Market Cap:
$40.93B
Revenue:
$5.72B
Net Income/Loss:
$4.17B
P/E Ratio:
10.26
EPS:
6.97
Net Cash Flow:
$259.90M
1W Performance:
+4.79%
1M Performance:
+1.27%
6M Performance:
+4.47%
1Y Performance:
-18.01%
1-Day Range:
$70.55
$72.15
1-Week Range:
$67.13
$72.15
52-Week Range:
$58.93
$95.25
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
71.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
|
ABT
Abbott Laboratories
|
130.98 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.12 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.50 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.60 | 108.02B | 33.20B | 4.26B | 5.47B | 3.29 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Edwards touts 8-year data for Resilia valve tissue - MassDevice
Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
Edwards Lifesciences (EW) Shares Surge on Promising Aortic Valve Study Results | EW Stock News - GuruFocus
Breakthrough: Edwards Heart Valves Achieve 99.3% Success Rate in Landmark 8-Year Study - Stock Titan
Is Edwards Lifesciences Gaining or Losing Market Support? - Benzinga
Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings - MSN
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025 - marketscreener.com
Q1 2025 Earnings Alert: Edwards Lifesciences Unveils Critical Financial Report Date - Stock Titan
Edwards Lifesciences Insider Sold Shares Worth $663,196, According to a Recent SEC Filing - marketscreener.com
Edwards Lifesciences CVP Donald Bobo Jr. sells $663k in stock - Investing.com Australia
Edwards Lifesciences (EW) Secures CE Mark for Innovative Mitral Valve System | EW Stock News - GuruFocus
Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System - BioSpace
Edwards Lifesciences CVP Donald Bobo Jr. sells $663k in stock By Investing.com - Investing.com South Africa
Edwards lands first CE mark for transfemoral mitral valve replacement - BioWorld MedTech
Edwards Lifesciences Gets CE Mark for Sapien M3 Mitral Valve System - MarketScreener
Edwards Sapien M3 Receives CE Mark, Becoming World'S First Transfemoral Transcatheter Mitral Valve Replacement System - MarketScreener
Edwards wins CE mark for Sapien M3 transfemoral heart valve - MassDevice
Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System – Company AnnouncementFT.com - Financial Times
Investors in Edwards Lifesciences Corporation Should Contact Levi & Korsinsky Before December 13, 2024 to Discuss Your RightsEW - marketscreener.com
Edwards Lifesciences Stock: A Deep Dive Into Analyst Perspectives (9 Ratings) - Benzinga
Truist Cuts Price Target on Edwards Lifesciences to $75 From $78, Keeps Hold Rating - MarketScreener
Edwards Lifesciences’ Quarterly Earnings Preview: What You Need to Know - Nasdaq
Edwards Lifesciences’ Quarterly Earnings Preview: What You Need To Know - Barchart.com
Edwards lifesciences CVP Daniel Lippis sells $21,183 in stock By Investing.com - Investing.com Canada
Edwards lifesciences CVP Daniel Lippis sells $21,183 in stock - Investing.com
CMS rolls out draft coverage memo for TEER for the tricuspid valve - BioWorld MedTech
Citigroup Adjusts Edwards Lifesciences Price Target to $84 From $83, Maintains Buy Rating - MarketScreener
Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry - Benzinga
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Medical Device Industry: Swept Up in the Tariffs, Diabetes Device Makers Bear the Brunt - Morningstar
Edwards Lifesciences (NYSE:EW) Presents Promising AS Treatment Data At ACC Session - Yahoo Finance
Edwards’ Early TAVR refutes surveillance recs for aortic stenosis - BioWorld MedTech
Sands Capital Select Growth Fund Sold Edwards Lifesciences Corporation (EW) For Better Opportunities - Yahoo Home
Jim Cramer Calls Edwards Lifesciences (EW) a Hold – Prefers Boston Scientific Right Now! - Insider Monkey
Edwards shares data supporting timely TAVR intervention - MassDevice
Huntington Beach man meets heart valve engineers who saved his life - Los Angeles Times
Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $85 From $92, Keeps Buy Rating - MarketScreener
Goldman Sachs Adjusts Price Target to Edwards Lifesciences to $85 From $92, Keeps Buy Rating - MarketScreener
Edwards Lifesciences CFO Scott Ullem sells $797,267 in stock - Investing.com
Edwards Lifesciences CFO Scott Ullem sells $797,267 in stock By Investing.com - Investing.com South Africa
Edwards Lifesciences: Double-Digit Top Line And EPS Growth Ahead - Seeking Alpha
S&P 500 Gains and Losses Today: Edwards Lifesciences Sinks on Outlook for Key Product - MSN
How Is The Market Feeling About Edwards Lifesciences? - Benzinga
Is Edwards Lifesciences Stock Underperforming the Nasdaq? - Nasdaq
Is Edwards Lifesciences Stock Underperforming The Nasdaq? - Barchart
Edwards Lifesciences downgraded at JPM, Truist on slower transcatheter valve growth - MSN
Edwards Lifesciences VP Donald Bobo Jr. sells $645,623 in stock By Investing.com - Investing.com Australia
Edwards Lifesciences VP Donald Bobo Jr. sells $645,623 in stock - Investing.com
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
Edwards Lifesciences Corp Stock (EW) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BOBO DONALD E JR | CVP,Strategy/Corp Development |
Apr 14 '25 |
Sale |
69.81 |
9,500 |
663,196 |
47,206 |
| Lippis Daniel J. | CVP, JAPAC |
Apr 08 '25 |
Option Exercise |
45.28 |
300 |
13,583 |
23,163 |
| Lippis Daniel J. | CVP, JAPAC |
Apr 08 '25 |
Sale |
70.61 |
300 |
21,183 |
22,863 |
1.45%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):